Dubai, UAE – 06 November 2024: A recent roundtable in Dubai brought together a distinguished panel of physicians and healthcare experts to discuss critical advancements and challenges in the diagnosis and treatment of Chronic Obstructive Pulmonary Disease (COPD). This event represents a significant step forward in identifying innovative and effective solutions for COPD, a condition that causes progressive lung function deterioration and impacts the lives of millions globally.
A central topic addressed was the worldwide challenge of underdiagnosed COPD cases. Many patients are unaware of their diagnosis until the disease has advanced, leading to delayed treatment and increased risk of severe complications. Smoking, particularly among youth and adolescents, remains a key factor driving the prevalence of COPD. This trend, coupled with the healthcare demands of respiratory illnesses, underscores the need for broad public awareness campaigns on the risks of smoking, occupational respiratory hazards, and the value of early respiratory health screenings. Detecting COPD in its early stages enables access to simpler, more effective treatments and enhances patient outcomes.
During the roundtable, Professor Bassam Mahboub, Head of the Respiratory Department at Rashid Hospital, underscored the breakthrough potential of biological therapies for COPD. “These treatments represent a transformative advancement in COPD management, giving patients a real opportunity to regain control over their lives,” said Professor Mahboub. He explained that biological therapies target chronic lung inflammation, a major driver of disease progression, leading to significant improvements in patients’ daily quality of life.
Adding to the discussion, Dr Hamad Alhameli, President of allergy and clinical immunology group under the Emirates Thoracic Society, highlighted the effectiveness of biological therapies as an alternative to traditional treatment options. “Biological therapies offer a promising approach, demonstrating marked improvements in reducing symptoms and enhancing lung function,” Dr. Alhameli stated. He further emphasized the importance of educating patients on the availability of these treatments, noting that “awareness and patient education are essential to improving treatment outcomes and empowering patients to better manage their condition.”
Participants also stressed the importance of collaborative efforts between pharmaceutical companies and healthcare providers to enhance treatment efficacy and provide support networks for COPD patients. Professor Mahboub expressed optimism about the adoption of biological therapies across the region, noting that “broader adoption of this approach will significantly elevate the quality of healthcare provided to COPD patients.”
This roundtable underscores the UAE’s commitment to advancing respiratory healthcare and highlights the critical role of early diagnosis, innovative treatment options, and ongoing patient education in improving COPD patient outcomes.
